共 50 条
Injectable biodegradable starch/chitosan delivery system for the sustained release of gentamicin to treat bone infections
被引:31
作者:
Balmayor, E. R.
[1
,2
]
Baran, E. T.
[1
,2
]
Azevedo, H. S.
[1
,2
]
Reis, R. L.
[1
,2
]
机构:
[1] Univ Minho, Res Grp Biomat Biodegradables & Biomimet 3Bs, Dept Polymer Engn, Headquarters European Inst Excellence Tissue Engn, P-4806909 Taipas, Guimaraes, Portugal
[2] IBB Inst Biotechnol & Bioengn, PT Associated Lab, Guimaraes, Portugal
关键词:
Starch-conjugated chitosan;
Gentamicin;
Microparticles;
Sustained release;
Staphylococcus aureus;
NUCLEAR-MAGNETIC-RESONANCE;
ORAL DELIVERY;
CHITOSAN;
MICROCAPSULES;
DEACETYLATION;
ANTIBIOTICS;
FABRICATION;
ASSIGNMENT;
CAPSULES;
DRUGS;
D O I:
10.1016/j.carbpol.2011.06.078
中图分类号:
O69 [应用化学];
学科分类号:
081704 ;
摘要:
Starch-conjugated chitosan microparticles were produced aimed to be used as a carrier for the long term sustained/controlled release of antibiotic drugs to control bone infection. The microparticles were prepared by a reductive alkylation crosslinking method. The obtained microparticles showed a spherical shape, with a slightly rough and porous surface, and a size range of 80-150 mu m. Gentamicin was entrapped into the starch-conjugated chitosan microparticles and its release profile was studied in vitro. Increasing concentrations of gentamicin (from 50 to 150 mg/mL) led to a decrease in the encapsulation efficiency (from 67 to 55%), while drug loading increased from 4 to 27%. A sustained release of gentamicin was observed over a period of 30 days. The release kinetics could be controlled using an ionic crosslinker agent. In addition, a bacterial inhibition test on Staphylococcus aureus shows a diameter of the sample inhibition zone ranging from 12 to 17 mm (70-100% of relative activity). (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:32 / 39
页数:8
相关论文
共 50 条